Rapt Ther­a­peu­tics winds down Phase 2 stud­ies of lead can­di­date in wake of clin­i­cal holds

Rapt Ther­a­peu­tics said it will close and un­blind two mid-stage tri­als in atopic der­mati­tis and asth­ma af­ter they were put on clin­i­cal hold ear­li­er this year due to a case of liv­er fail­ure.

The com­pa­ny is now work­ing to clean the atopic der­mati­tis da­ta and an­tic­i­pates com­plet­ing its analy­sis in the third quar­ter. It is al­so con­tin­u­ing to in­ves­ti­gate the se­ri­ous ad­verse event that trig­gered the clin­i­cal holds.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER